2019-002626-67: EFFICACY AND SAFETY OF THE COMBINATION OF BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS EVALUACIÓN DE LA EFICACIA Y SEGURIDAD DE LA COMBINACIÓN DE BORTEZOMIB, LENALIDOMIDA Y DEXAMETASONA EN PACIENTES CON MIELOMA MÚLTIPLE DE NUEVO DIAGNÓSTICO |
|
|
| Not yet recruiting | 4 | 360 | Europe | bortezomib, Revlimid, Dexamethasone, Revlimid, S02BA06, Powder and solution for solution for injection, Capsule, hard, Tablet, Velcade, Revlimid, Dexamethasone | Institut Català d'Oncologia, Institut Català d'Oncologia | Multiple myeloma Mieloma múltiple, Multiple myeloma mieloma múltiple, Diseases [C] - Cancer [C04] | | | | |
US MM-6, NCT03173092: A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) |
|
|
| Active, not recruiting | 4 | 141 | US | Ixazomib, NINLARO, MLN9708, Lenalidomide, Dexamethasone | Takeda | Multiple Myeloma | 11/26 | 11/26 | | |
RESTORE, NCT06015750: Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia |
|
|
| Not yet recruiting | 4 | 8 | NA | methotrexate, rituximab, bortezomib, IVIg, Folic Acid | Alexion Pharmaceuticals, Inc. | Hypophosphatasia | 04/28 | 04/28 | | |
